These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

116 related items for PubMed ID: 1820436

  • 1. Effects of dietary phosphorus restriction on secondary hyperparathyroidism in hemodialysis patients during intermittent oral high-dose 1,25(OH)2D3 treatment.
    Tabata T, Shoji S, Morita A, Emoto M, Inoue T, Miki T, Nishizawa Y, Morii H.
    J Nutr Sci Vitaminol (Tokyo); 1991 Dec; 37 Suppl():S105-12. PubMed ID: 1820436
    [Abstract] [Full Text] [Related]

  • 2. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L.
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [Abstract] [Full Text] [Related]

  • 3. Suppression of secondary hyperparathyroidism in chronic dialysis patients by single oral weekly dose of 1,25-dihydroxycholecalciferol.
    Shigematsu T, Kawaguchi Y, Unemura S, Yamamoto H, Momose M, Yokoyama K, Wakabayashi Y, Ikeda M, Hasegawa T, Sakai O.
    Intern Med; 1993 Sep; 32(9):695-701. PubMed ID: 8142673
    [Abstract] [Full Text] [Related]

  • 4. The 'oral 1,25-dihydroxyvitamin D3 pulse therapy' in hemodialysis patients with severe secondary hyperparathyroidism.
    Tsukamoto Y, Nomura M, Takahashi Y, Takagi Y, Yoshida A, Nagaoka T, Togashi K, Kikawada R, Marumo F.
    Nephron; 1991 Sep; 57(1):23-8. PubMed ID: 2046811
    [Abstract] [Full Text] [Related]

  • 5. Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25-dihydroxy-cholecalciferol in uremic patients.
    Slatopolsky E, Weerts C, Thielan J, Horst R, Harter H, Martin KJ.
    J Clin Invest; 1984 Dec; 74(6):2136-43. PubMed ID: 6549016
    [Abstract] [Full Text] [Related]

  • 6. Effect of intermittent oral 1,25(OH)2D3 therapy on bone Gla protein in dialysis patients.
    Miki T, Nakatsuka K, Nishizawa Y, Emoto M, Morita A, Tabata T, Matsushita Y, Inoue T, Morii H.
    Endocrinol Jpn; 1991 Oct; 38(5):479-83. PubMed ID: 1843267
    [Abstract] [Full Text] [Related]

  • 7. Comparative effect of oral or intravenous calcitriol on secondary hyperparathyroidism in chronic hemodialysis patients.
    Liou HH, Chiang SS, Huang TP, Shieh SD, Akmal M.
    Miner Electrolyte Metab; 1994 Oct; 20(3):97-102. PubMed ID: 7816008
    [Abstract] [Full Text] [Related]

  • 8. Treatment of severe secondary hyperparathyroidism with administration of calcium carbonate, intermittent high oral doses of 1,25-dihydroxyvitamin D3 and dialysate with 3 mEq/1 calcium concentration.
    Perez-Mijares R, Gomez-Fernandez P, Almaraz-Jimenez M, Ramos-Diaz M, Rivero-Bohorquez J.
    Am J Nephrol; 1993 Oct; 13(2):149-54. PubMed ID: 8342582
    [Abstract] [Full Text] [Related]

  • 9. 'Pulse oral' versus intravenous calcitriol therapy in chronic hemodialysis patients. A prospective and randomized study.
    Bacchini G, Fabrizi F, Pontoriero G, Marcelli D, Di Filippo S, Locatelli F.
    Nephron; 1997 Oct; 77(3):267-72. PubMed ID: 9375818
    [Abstract] [Full Text] [Related]

  • 10. Intravenous calcitriol for treatment of hyperparathyroidism in children on hemodialysis.
    Greenbaum LA, Grenda R, Qiu P, Restaino I, Wojtak A, Paredes A, Benador N, Melnick JZ, Williams LA, Salusky IB.
    Pediatr Nephrol; 2005 May; 20(5):622-30. PubMed ID: 15785941
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Long-term control of hyperparathyroidism in advanced renal failure by low-phosphorus low-protein diet supplemented with calcium (without changes in plasma calcitriol).
    Combe C, Morel D, de Précigout V, Blanchetier V, Bouchet JL, Potaux L, Fournier A, Aparicio M.
    Nephron; 1995 May; 70(3):287-95. PubMed ID: 7477615
    [Abstract] [Full Text] [Related]

  • 16. Long-term effects of intravenous 1 alpha (OH)D3 combined with CaCO3 and low-calcium dialysis on secondary hyperparathyroidism and biochemical bone markers in patients on chronic hemodialysis.
    Brandi L, Daugaard H, Nielsen PK, Jensen LT, Egsmose C, Olgaard K.
    Nephron; 1996 May; 74(1):89-103. PubMed ID: 8883025
    [Abstract] [Full Text] [Related]

  • 17. A crossover comparison of intermittent oral and intravenous administration of calcitriol on the parathyroid hormone concentration in hemodialysis patients.
    Peng SJ, Yang CS, Ferng SH, Chen LY.
    Miner Electrolyte Metab; 1997 May; 23(1):13-8. PubMed ID: 9058364
    [Abstract] [Full Text] [Related]

  • 18. Pulse oral versus pulse intraperitoneal calcitriol: a comparison of efficacy in the treatment of hyperparathyroidism and renal osteodystrophy in peritoneal dialysis patients.
    Gadallah MF, Arora N, Torres C, Ramdeen G, Schaeffer-Pautz A, Moles K.
    Adv Perit Dial; 2000 May; 16():303-7. PubMed ID: 11045316
    [Abstract] [Full Text] [Related]

  • 19. Treatment of refractory hyperparathyroidism in patients on hemodialysis by intermittent oral administration of 1,25(OH)2vitamin D3.
    Muramoto H, Haruki K, Yoshimura A, Mimo N, Oda K, Tofuku Y.
    Nephron; 1991 May; 58(3):288-94. PubMed ID: 1896093
    [Abstract] [Full Text] [Related]

  • 20. Successful Conversion From Parenteral Paricalcitol to Pulse Oral Calcitriol for the Management of Secondary Hyperparathyroidism in Hemodialysis Patients.
    Kumar J, Tran NT, Schomberg J, Streja E, Kalantar-Zadeh K, Pahl M.
    J Ren Nutr; 2016 Jul; 26(4):265-9. PubMed ID: 27038806
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.